European Heart Journal vs Lancet Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. Lancet Oncology asks whether the paper changes oncology practice at a global level.

That difference should drive the submission choice.

If the manuscript depends on ESC relevance, cardiovascular surveillance, imaging, heart-failure logic, or cardiac risk interpretation, EHJ usually becomes the better home. If the manuscript depends on oncology trial logic, treatment standards, global clinical consequence, or practice change for oncologists, Lancet Oncology usually becomes the better home.

EHJ wins when the cardio-oncology manuscript is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity surveillance and monitoring
• cardiovascular outcomes after cancer therapy
• imaging or biomarker work that cardiologists must act on
• registries and outcome analyses with a cardiovascular practice consequence

EHJ's editorial guidance are clear that the journal wants broad cardiology consequence and a field-facing cardiovascular story.

Lancet Oncology wins when the manuscript is fundamentally an oncology paper.

That includes:

• clinical trials where the main message is cancer treatment strategy
• oncology practice change with important but secondary cardiovascular findings
• survivorship or toxicity work that mainly changes oncologist behavior
• globally relevant oncology evidence with strong clinical consequences

Lancet Oncology's editorial guidance are explicit that the journal wants papers that change what oncologists do, not just interesting mechanism or local observation.

EHJ submission's editorial guidance emphasizes ESC guidelines, European cardiovascular practice, structured abstracts, graphical abstracts, and cardiology-facing significance. That means the paper belongs there only if the cardiovascular consequence is the actual lead.

The Lancet Oncology source set emphasizes Research in Context, in-house statistical review, and practice-changing clinical relevance. It isn't enough to be oncology-adjacent. The study has to matter to how oncologists practice.

Cardiology language, risk logic, and imaging or outcomes nuance are expected there.

If the manuscript is still fundamentally about treatment, cancer outcomes, or global oncology practice, that's a strength there, not a weakness.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• cardiovascular surveillance, outcomes, or ESC relevance are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally oncology-led
• oncologists are the main audience
• treatment strategy or global oncology consequence is central
• the manuscript becomes stronger when written for oncology readers

That's the Lancet Oncology lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become a Lancet Oncology paper, and vice versa.

The cascade only works when the first journal saw the manuscript as belonging more naturally to the other specialty.

That can happen when:

• the paper sits at the cardio-oncology boundary
• the methods are strong
• the question matters to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the study is simply too narrow or too weak for either field-leading journal.

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

If the main action belongs to cardiologists and the oncology context is mostly background, Lancet Oncology gets harder quickly.

The journal still wants field-wide cardiology relevance, not only competent cardio-oncology analysis.

The journal's editorial guidelines are blunt that early, weakly validated, or non-clinical oncology stories struggle badly there.

These are usually cleaner EHJ papers when the goal is to change cardiovascular practice.

These are often cleaner Lancet Oncology papers when the main consequence is still oncology treatment strategy.

This category can go either way. If the primary field that needs to act is cardiology, EHJ usually wins. If the primary field is oncology, Lancet Oncology usually wins.

The key question is whether the paper is really about cancer practice or cardiac management. That usually tells you the right target.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong Lancet Oncology first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If you need both first pages at once, the paper may still be undecided about its true audience.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think worldwide" points toward Lancet Oncology

That sentence is often the most honest submission test.

At the cardio-oncology boundary, the wrong readership can flatten a very strong paper. A study that's excellent for cardiologists can look too secondary to oncologists. A study that's excellent for oncologists can look only indirectly actionable for cardiologists.

That's why audience clarity matters more than brand reflexes in this comparison.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to Lancet Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. treatment strategy or global oncology practice is central
4. the paper gets stronger when written for oncology

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.

Submit to European Heart Journal first if:

• The manuscript is fundamentally cardiovascular: cardiotoxicity, cardiovascular outcomes after cancer therapy, imaging, or biomarker work that cardiologists must act on
• The ESC guidelines or European cardiovascular practice context is central to the paper's significance
• Cardiologists are the primary audience and the paper makes them better at cardiovascular management

Think twice about EHJ if:

• The cardiovascular findings are important but secondary to the oncology story; EHJ will see the misframe quickly and the paper will not pass triage
• You are submitting to EHJ because the impact factor is higher than specialty oncology journals, not because cardiology is the right readership; brand logic without audience fit is a fast desk rejection
• The paper requires oncology treatment context that most cardiologists would need explained; that signals the wrong home

Submit to Lancet Oncology first if:

• The paper is fundamentally oncology-led: cancer treatment strategy, global oncology practice change, survivorship, or toxicity work that mainly changes oncologist behavior
• The primary consequence is what oncologists do with the result, even if cardiovascular endpoints are important in the study
• The paper has the global clinical relevance Lancet Oncology's editorial guidance requires

Think twice about Lancet Oncology if:

• The paper is primarily about how cardiologists should manage cardiovascular complications; Lancet Oncology will redirect that to a cardiology journal
• The oncology evidence is early-phase or not yet practice-changing; Lancet Oncology is explicit that it does not publish preliminary findings without a clear clinical practice argument
• The study is regionally focused without global oncology relevance; the Lancet family journals expect evidence that matters beyond one healthcare system

In our pre-submission review work with manuscripts targeting both European Heart Journal and Lancet Oncology, three patterns generate the most consistent mismatch decisions among the papers we analyze.

Cardio-oncology papers submitted to EHJ where the cardiovascular findings are secondary. The most common problem we see is a cancer trial paper with important cardiovascular safety data submitted to EHJ. The study is well-conducted and the cardiovascular data is real, but the primary endpoint is oncological and the paper's main message is about treatment strategy for oncologists. EHJ editors recognize this structure quickly. The paper belongs in an oncology journal, and the desk rejection usually arrives within two weeks.

Lancet Oncology submissions where practice-changing evidence is overstated. Lancet Oncology requires that manuscripts demonstrate genuine practice change, not just strong correlation or interesting mechanism. We see papers with high-quality observational data or secondary analyses positioned as practice-changing when the evidence level does not support that frame. Lancet Oncology's in-house statistical review and Research in Context requirement make it difficult to overstate the clinical evidence without triggering desk rejection.

Undecided audience papers where both journals were wrong. Some cardio-oncology papers genuinely could not be clearly written for either cardiologists or oncologists as the primary audience. When we see these, the manuscript is usually at an early stage of framing. The paper needs to decide whose clinical behavior it is meant to change before it can be written for either journal. Submitting to either flagship before that decision is clear tends to produce two rapid desk rejections rather than one.

SciRev author-reported data confirms that European Heart Journal's median time to first decision is typically around 3 to 5 weeks, and Lancet Oncology's is typically around 2 to 3 weeks. A EHJ vs. Lancet Oncology framing and positioning check can identify whether your manuscript is correctly positioned for the journal you're targeting before you submit.

• European Heart Journal submission guide
• Lancet Oncology submission guide
• Is Lancet Oncology a good journal?
• European Heart Journal - Author Guidelines
• Lancet Oncology - Author Guidelines
• Clarivate Journal Citation Reports (JCR 2024)